Prostaglandin E1 (PGE1) is a natural endogenous physiological active substance with many physiological and pharmacological effects. It can be used to prevent and treat various cardiovascular and cerebrovascular diseases, hyperlipidemia, renal insufficiency, bronchial asthma and other diseases. However, PGE1 has low water solubility, unstable chemical properties and is sensitive to acid, alkali, humidity and heat. These shortcomings seriously affect the research and development of its preparation.
The introduction of hydroxypropyl group breaks the cyclic hydrogen bond in the molecule of beta-cyclodextrin and overcomes the main shortcomings of poor water solubility of beta-cyclodextrin while keeping the cavity of beta-cyclodextrin. It is one of the most deeply studied and widely used cyclodextrin derivatives, mainly used in food, medicine and cosmetics industry.
Therefore, by embedding PGE1 with hydroxypropyl beta-cyclodextrin and making nasal powder and sublingual tablets from inclusions, the problem of poor chemical stability of PGE1 preparation can be solved, thus becoming a new PGE1 preparation with convenient use, less adverse reactions, good absorption and extensive clinical application.